Stifel Nicolaus Remains a Buy on HEALWELL AI (AIDX)
In a report released today, Justin Keywood from Stifel Nicolaus maintained a Buy rating on HEALWELL AI, with a price target of C$3.80.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Keywood covers the Healthcare sector, focusing on stocks such as WELL Health Technologies Corp, kneat.com, and HLS Therapeutics Inc. According to TipRanks, Keywood has an average return of -3.5% and a 48.85% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for HEALWELL AI with a C$3.20 average price target.
Based on HEALWELL AI’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of C$30.35 million and a GAAP net loss of C$27.86 million. In comparison, last year the company earned a revenue of C$13.74 million and had a GAAP net loss of C$10.57 million
Read More on TSE:AIDX:
Disclaimer & DisclosureReport an Issue
- HEALWELL AI Wins Major U.S. HIE Deal as AI-Enabled Platform Gains Global Traction
- HEALWELL AI Steps Up Investor Outreach With March Conference Lineup
- HEALWELL AI: Scaling Government-Grade Healthcare AI With Recurring SaaS and Strategic Cross-Sell Synergies
- HEALWELL AI Enters Middle East as Enterprise Healthcare Deployments Accelerate
- HEALWELL AI and WELL Health Unveil WELLTRUST Platform for Ethical AI-Driven Clinical Trial Recruitment
